Oxford Square Capital Corp. announced it will hold a conference call on October 30, 2026, at 9:00 AM Eastern time to discuss its third quarter 2026 earnings. Investors can join the call via a toll-free number, and a recorded replay will be available for 30 days afterward. The company primarily invests in syndicated bank loans and collateralized loan obligation vehicles. This call provides an opportunity for investors to hear directly about the company's recent financial performance and outlook.
Oxford Square Capital Corp.'s upcoming Q3 2026 earnings call is noted here as context for financial sector activity on Pluang. For readers following Financials, as of Oct 24, 2026 03:52 WIB, 39 of 142 priced US Financial stocks rose while 103 fell. Flagstar Bank NA (FLG) dropped 9.25% to USD 10.40 with 100% buy orders and a typical hold time of 20 days, contrasting with Carlyle Group Inc (CG) which gained 5.15% to USD 39.19 and a much longer hold time of 113 days. Bit Digital Inc (BTBT) fell 6.13% to USD 0.85 with predominantly sell orders at 81%.
The documentary 'NURSE: Empathy Heals' premiered on October 21 in Nashville, showcasing personal stories of nurses and the critical role of empathy in healthcare. It highlights the emotional challenges nurses face, especially during crises like the C...
Del Valle ISD Education Foundation in Austin, Texas, received the F1 Allwyn Global Community Award and a €100,000 grant from Allwyn during the 2026 Formula 1 United States Grand Prix. The funding supports the Fast Track initiative, which provides sch...
The Del Valle ISD Education Foundation in Austin, Texas, received the F1 Allwyn Global Community Award and a €100,000 grant from Allwyn to fund its 'Fast Track' initiative. This program aims to support 12,000 students by providing scholarships, teach...
The Del Valle ISD Education Foundation in Austin received the F1® Allwyn Global Community Award, securing a €100,000 grant from Allwyn to fund its Fast Track program. This initiative supports 12,000 students in disadvantaged areas by providing STEM s...
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
